NCT04069819View on ClinicalTrials.gov

The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Major Depressive Disorder
Interventions
DRUG

Cilostazol 50 MG Oral Tablet

Escitalopram,Selective serotonin reuptake inhibitor- Cilostazol, a selective phosphodiesterase 3 (PDE3) inhibitor, acts as an antiplatelet agent and has been widely approved for treatment of intermittent claudication with peripheral arterial disease and for secondary prevention of ischemic stroke.

DRUG

Escitalopram

Escitalopram 20 mg tablet once daily for 6 week

DRUG

Placebo

placebo

Trial Locations (1)

Unknown

Faculty of Medicine, Shibīn al Kawm

All Listed Sponsors
lead

Sadat City University

OTHER

NCT04069819 - The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. | Biotech Hunter | Biotech Hunter